Abstract Peripheral facial paralysis (PFP) has been shown to be a neurological manifestation of COVID-19. The current study presents two cases of PFP after COVID-19, along with a rapid review of known cases in the literature. Both case reports were conducted following CARE guidelines. We also performed a systematic review of PFP cases temporally related to COVID-19 using PubMed, Embase, and Cochrane Library databases on August 30, 2021, using a rapid review methodology. The two patients experienced PFP 102 and 110 days after COVID-19 symptom onset. SARS-CoV-2 RNA was detected in nasal samples through reverse-transcription real-time polymerase chain reaction (RT-qPCR) testing. Anosmia was the only other neurological manifestation. PFP was treated with steroids in both cases, with complete subsequent recovery. In the rapid review, we identified 764 articles and included 43 studies. From those, 128 patients with PFP were analyzed, of whom 42.1% (54/128) were male, 39.06% (50/128) female, and in 23 cases the gender was not reported. The age range was 18 to 59 (54.68%). The median time between COVID-19 and PFP was three days (ranging from the first symptom of COVID-19 to 40 days after the acute phase of infection). Late PFP associated with COVID-19 presents mild symptoms and improves with time, with no identified predictors. Late PFP should be added to the spectrum of neurological manifestations associated with the long-term effects of SARS-CoV-2 infection as a post COVID-19 condition.

RESUMO Objetivo: Como a infecção por SARS-CoV-2 pode afetar gravemente os pulmões e podem ocorrer alterações funcionais persistentes após doença grave, nosso objetivo foi determinar os parâmetros de função pulmonar de pacientes com COVID-19, 45 dias após a alta hospitalar e comparar as alterações de acordo com a gravidade da doença. Métodos: Estudo multicêntrico, prospectivo, descritivo e analítico. Os participantes foram alocados em três grupos: grupo internação em enfermaria (IE); grupo internação em UTI sem ventilação mecânica (UTI/VM−); e grupo internação em UTI com VM (UTI/VM+). Volumes pulmonares, DLCO, PImáx, PEmáx e distância percorrida no teste de caminhada de seis minutos (DTC6) foram medidos 45 dias após a alta. Resultados: A amostra foi composta por 242 pacientes (média de idade = 59,4 ± 14,8 anos; 52,1% do sexo masculino), e 232 (96%) apresentavam alteração da função pulmonar. Na coorte total, observou-se distúrbio restritivo em 96%, assim como redução da DLco (em 21,2% dos pacientes), VEF1/CVF (em 39,7%) e PEmáx (em 95,8%), sem diferença entre os grupos para todos. Na comparação entre os grupos, o grupo UTI/VM+ apresentou DLCO reduzida em 50% dos pacientes (p < 0,001) e teve menor média da DTC6 do valor previsto (p = 0,013). Dessaturação de oxigênio no teste de caminhada de seis minutos foi observada em 32,3% da coorte e foi menos frequente no grupo IE. Conclusões: Este é o primeiro estudo sul-americano envolvendo sobreviventes de COVID-19 grave cuja função pulmonar foi avaliada 45 dias após a alta hospitalar. Alterações foram frequentes, principalmente naqueles em VM, o que destaca a importância da avaliação da função pulmonar após COVID-19 grave.

ABSTRACT Objective: Because SARS-CoV-2 infection can severely affect the lungs and persistent functional changes can occur after severe disease, we aimed to determine lung function parameters of COVID-19 patients at 45 days after hospital discharge and compare changes according to the severity of the disease. Methods: This was a prospective descriptive analytical multicenter study. The participants were allocated into three groups: ward admission (WA) group; ICU admission not on mechanical ventilation (ICU/MV−) group; and ICU admission on MV (ICU/MV+) group. Lung volumes, DLco, MIP, MEP, and six-minute walk distance (6MWD) were measured 45 days after discharge. Results: The sample comprised 242 patients (mean age = 59.4 ± 14.8 years; 52.1% of males), and 232 (96%) had altered lung function. In the total cohort, restrictive disorder was observed in 96%, as well as reductions in DLco (in 21.2% of the patients), FEV1/FVC (in 39.7%), and PEmax (in 95.8%), with no differences between the groups. Comparing the groups, the ICU/MV+ group had reduced DLco in 50% of the patients (p < 0.001) and a lower mean 6MWD % of the predicted value (p = 0.013). Oxygen desaturation in the six-minute walk test was observed in 32.3% of the cohort and was less frequent in the IE group. Conclusions: This is the first South American study involving severe COVID-19 survivors whose lung function was assessed 45 days after hospital discharge. Changes were frequent, especially in those on MV, which highlights the importance of lung function evaluation after severe COVID-19.

A associação de poliartrite, nódulos subcutâneos e carcinoma de pâncreas é uma condição rara e pouco diagnosticada. O presente trabalho tem o objetivo de relatar um caso de carcinoma pancreático associado a poliartrite e nódulos subcutâneos, semelhantes ao eritema nodoso, cujo exame histopatológico evidenciou tratar-se de paniculite com necrose gordurosa. Os autores pretendem, por meio deste relato, lembrar essa associação incomum que se torna de grande importância clínica, considerando que artrite e nódulos subcutâneos podem anteceder as manifestações clínicas de neoplasia pancreática.

The association of polyarthritis, subcutaneous nodules and carcinoma of the pancreas is a rare and underdiagnosed condition. The present work aims to report a case of a patient with carcinoma of pancreas associated with polyarthritis and subcutaneous nodules, similar to erythema nodosum, with histopathological findings of panniculitis with fat necrosis. The authors emphasize the importance of this uncommon association, considering that polyarthritis and subcutaneous nodules may appear before the clinical manifestations of the carcinoma of the pancreas.